Medpace Holdings Inc. (MEDP)
Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider
Medpace (MEDP) closed the most recent trading day at $305.90, moving +2.54% from the previous trading session.
Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2025 Earnings Conference Call April 22, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Ann Hynes - Mizuho Dan Leonard - UBS Eric Coldwell - Baird Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Justin Bowers - Deutsche Bank Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode.
Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates
Medpace (MEDP) came out with quarterly earnings of $3.67 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $3.20 per share a year ago.
Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Medpace (MEDP) closed at $290.10, marking a +1.04% move from the previous day.
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit.
Medpace Holdings: It Might Be Time To Buy In
Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties around pharmaceutical spending and backlogs, which could make the current valuation appear too high.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Medpace (MEDP) closed at $330.59 in the latest trading session, marking a +1.96% move from the prior day.
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
Medpace (MEDP) concluded the recent trading session at $324.13, signifying a +1.55% move from its prior day's close.
Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q4 2024 Earnings Conference Call February 11, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Max Smock - William Blair Eric Coldwell - Baird David Windley - Jefferies Jailendra Singh - Truist Securities Justin Bowers - Deutsche Bank Charles Rhyee - TD Cowen Ann Hynes - Mizuho Operator Good day, ladies and gentlemen, and welcome to the Medpace Fourth Quarter and Full-Year 2024 Earnings Conference Call. At this time, all participants are in listen-only mode.
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates
Medpace (MEDP) came out with quarterly earnings of $3.67 per share, beating the Zacks Consensus Estimate of $2.97 per share. This compares to earnings of $2.46 per share a year ago.
Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential
Medpace has had an excellent financial performance. Its revenues increased by 495.26% between 2016Q2 and 2024Q3. Meanwhile, its current ROE is 54.08%. The company focused on small and mid-size companies. In this segment, the company has gained competitive advantages. Despite the fact that Medpace has received high backlog cancellations, the company is still a solid firm, and it grew by 9.81% between 2023 and 2024Q3 TTM.
